New cream could ease painful skin condition lichen sclerosus

NCT ID NCT07335588

Recruiting now Disease control Sponsor: LEO Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study tests a cream called delgocitinib for lichen sclerosus, a skin condition that causes itching, pain, and scarring in the genital area. About 652 adults with mild to severe disease will apply the cream twice daily for up to 52 weeks. Researchers will check if the cream improves skin appearance and reduces pain better than a placebo cream.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lichen sclerosus et atrophicus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LICHEN SCLEROSUS

Contacts and locations

Locations

LEO Pharma Investigational Site
RECRUITING

Birmingham, Alabama, 35244, United States
LEO Pharma Investigational Site
RECRUITING

Washington D.C., District of Columbia, 20037, United States
LEO Pharma Investigational Site
RECRUITING

Miami, Florida, 33186, United States
LEO Pharma Investigational Site
RECRUITING

Tamarac, Florida, 33321, United States
LEO Pharma Investigational Site
RECRUITING

New York, New York, 10036, United States
LEO Pharma Investigational Site
RECRUITING

Bexley, Ohio, 43209, United States
LEO Pharma Investigational Site
RECRUITING

Winnipeg, Manitoba, R3M 3Z4, Canada
LEO Pharma Investigational Site
RECRUITING

Guelph, Ontario, N1L 0B7, Canada
LEO Pharma Investigational Site
RECRUITING

Newmarket, Ontario, L3Y 2R2, Canada
LEO Pharma Investigational Site
RECRUITING

Richmond Hill, Ontario, L4E 4L6, Canada
LEO Pharma Investigational Site
RECRUITING

Toronto, Ontario, M3B 0A7, Canada
LEO Pharma Investigational Site
RECRUITING

Toronto, Ontario, M4W 2N4, Canada
LEO Pharma Investigational Site
RECRUITING

Waterloo, Ontario, N2J 1C4, Canada
LEO Pharma Investigational Site
RECRUITING

Montreal, Quebec, H1Y3L1, Canada
LEO Pharma Investigational Site
RECRUITING

Québec, Quebec, G1W 4R4, Canada
LEO Pharma Investigational Site
RECRUITING

Saskatoon, Saskatchewan, S7K 2C1, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.